CC-HS treatment is an acute model for AMD that likely conceals subtle differences between the two CFH genotypes, but this model does extend our current understanding of the role complement proteins play in inducing sub-RPE deposits and RPE atrophy. The gene discussed is VTN; the disease is Atrophy.